Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 44
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47

Pre-clinical development of AP4B1 gene replacement ther...

 48

Metabolic immaturity and breastmilk bile acid metabolites are central determinants of heightened newborn vulnerability to norovirus diarrhea

Metabolic immaturity and breastmilk bile acid metabolit...

 29

Interorganelle phospholipid communication, a house not so divided

Interorganelle phospholipid communication, a house not ...

 55